Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5

por Huang, Feng, Sun, Fei, Wan, Wei-Guo, Wu, Li-Jun, Dong, Ling-Li, Zhang, Xiao, Kim, Tae-Hwan, Sengupta, Raj, Šenolt, Ladislav, Wang, Yi, Qiu, Hao-Min, Porter, Brian, Haemmerle, Sibylle
Publicado 2020